Stock Ticker

  • Loading stock data...

What Is Going On With Plandai Biotechnology Inc (OTCMKTS:PLPL) And Amgen, Inc. (NASDAQ:AMGN)?

Plandai Biotechnology Inc (OTCMKTS:PLPL) is one of the OTC traded stocks that have been under investors radar in this year. Recently, the company confirmed an amendment to its previously finalized contract with USN Worldwide. As per the new deal, Plandai will expand its Phytofare® complex sales to USN and related contract manufacturer entities to the European Union.

The management stated that they are thrilled to expand deal with USN into the European Union market. It comes as a big opportunity that will help company boost its Phytofare® catechin ingredient sales in the respective region. As a leader firm in wellness and sports nutrition, USN is well acquainted with the many benefits of phyto-availability within its product line-up.

Generex Biotechnology Corporation (OTCMKTS:GNBT) Updates On Generex Oral-lyn™.

Generex Biotechnology updated its shareholders on the progress of its lead drug Generex Oral-lyn™. It released a white paper detailing the status of Generex Oral-lyn™ at annual meeting of stockholders. As per the update, the company achieved success in its initial measures to improve Generex Oral-lyn™ by making necessary changes in insulin concentrations.

The white paper highlighted Generex’s measures in the development of an alternative measure for injection of insulin into the human body. Generex Oral-lyn™ is a buccal insulin spray product that will allow diabetic patients to get rid of the inconvenience of injections whilst enhancing the metabolic benefit of the dosed insulin.

FDA Approves Amgen, Inc. (NASDAQ:AMGN) Medication Repatha™

Amgen reported that the U.S. FDA has approved its cholesterol-lowering medication, Repatha™ Injection. The medication is a human monoclonal antibody that stalls PCSK9, a protein that lowers the liver’s ability to eliminate low-density LDL-C from the blood. It is stated as an add-on to diet and a therapy for the cure of adults suffering with HeFH or ASCVD, who need additional reduction of LDL-C.

In last trading session, the stock price of Plandai Biotechnology jumped more than 10% to close the day at $0.13905.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at [email protected] or follow Nicholas Kitonyi @nmaithyak on Twitter.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts